Disease Domain | Count |
---|---|
Neoplasms | 7 |
Hemic and Lymphatic Diseases | 1 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 5 |
Herbal medicine | 1 |
Antibody drug conjugate (ADC) | 1 |
Proteolysis-targeting chimeras | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism BRAF inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism EGFR antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jan 2024 |
Sponsor / Collaborator |
Start Date01 Nov 2023 |
Sponsor / Collaborator |
Start Date01 Jan 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Baichuan Jiangya Capsule | Hypertension More | Phase 2 |
SR-38832 ( TFs and related regulators ) | Colorectal Cancer More | Preclinical |
W941 ( PI3K family ) | Non-Small Cell Lung Cancer More | Preclinical |
W922 ( BRAF ) | Neoplasms More | Preclinical |
Os30 ( EGFR ) | Neoplasms More | Preclinical |